Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

80.35USD
23 May 2017
Change (% chg)

$1.40 (+1.77%)
Prev Close
$78.95
Open
$78.90
Day's High
$80.50
Day's Low
$75.70
Volume
290,621
Avg. Vol
219,106
52-wk High
$100.40
52-wk Low
$36.62

Latest Key Developments (Source: Significant Developments)

Bluebird bio Q1 total revenue $6.8 million
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Bluebird Bio Inc ::Bluebird bio reports first quarter 2017 financial results and recent operational progress.Qtrly net loss per share - basic and diluted $ 1.68.Qtrly total revenue $ 6.8 million versus $ 1.5 million.Q1 earnings per share view $-1.78, revenue view $2.1 million -- Thomson Reuters I/B/E/S.Bluebird Bio Inc- ended quarter with $799.9 million in cash, cash equivalents and marketable securities.  Full Article

Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies
Tuesday, 2 May 2017 08:00am EDT 

May 2 (Reuters) - Bluebird Bio Inc :Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies.Bluebird bio - under terms of agreement, gsk will non-exclusively license certain bluebird patent rights related to lentiviral vector technology.Bluebird bio- financial terms of agreement include an upfront payment to bluebird as well as potential development and regulatory milestone payments.Bluebird bio inc - financial terms of agreement also include low single digit royalties on net sales of covered products.  Full Article

Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma
Tuesday, 2 May 2017 08:00am EDT 

May 2 (Reuters) - Bluebird Bio Inc :Bluebird bio inc- entered into a worldwide license agreement around its proprietary lentiviral vector platform with novartis pharma ag.Bluebird bio inc- financial terms of agreement with novartis include an upfront payment to bluebird as well as milestone and royalty payments.Bluebird bio-under terms novartis to non-exclusively license certain of co's patent rights to develop, commercialize chimeric antigen receptor t cell therapies for oncology.  Full Article

Bluebird bio qtrly net loss per share $1.88
Wednesday, 22 Feb 2017 04:05pm EST 

Bluebird Bio Inc : Bluebird Bio reports fourth quarter and full year 2016 financial results and recent operational progress . Bluebird Bio Inc - collaboration revenue was $1.6 million for Q4 of 2016 compared to $1.5 million . Bluebird Bio - expects cash, cash equivalents of $884.8 million as of Dec 31, 2016 to be sufficient to fund its current operations into H2 of 2019 .Bluebird Bio Inc qtrly net loss per share - basic and diluted $1.88.  Full Article

Bluebird Bio Inc commenced an underwritten public offering of $200 mln of its common stock
Tuesday, 6 Dec 2016 04:19pm EST 

Bluebird Bio Inc : Bluebird Bio Inc - has commenced an underwritten public offering of $200 million of its common stock .Bluebird bio announces proposed public offering of common stock.  Full Article

Proteostasis Therapeutics says appointment of James M. Detore as CFO
Monday, 8 Aug 2016 10:54am EDT 

Proteostasis Therapeutics Inc : Says appointment of James M. Detore as Chief Financial Officer .Detore joins company from Bluebird Bio, Inc.  Full Article

Bluebird bio reports qtrly loss per share of $1.59
Wednesday, 3 Aug 2016 04:05pm EDT 

Bluebird Bio Inc : Bluebird bio reports second quarter 2016 financial results and recent operational progress . Qtrly loss per share $1.59 .Q2 earnings per share view $-1.44 -- Thomson Reuters I/B/E/S.  Full Article

Bluebird Bio says co, Lonza Houston enter into manufacturing agreement
Thursday, 9 Jun 2016 08:20am EDT 

Bluebird Bio Inc : Bluebird Bio Inc says Lonza Houston Inc and co have entered into a strategic manufacturing agreement .Says agreement provides for future commercial production of Bluebird Bio's Lenti-D and Lentiglobin drug products..  Full Article

bluebird bio announces transition of chief financial officer
Thursday, 25 Feb 2016 04:05pm EST 

bluebird bio:Says that Jim DeTore, chief financial officer, has decided to leave the company, effective March 18.Bluebird bio is appointing Jeffrey Walsh as chief financial and strategy officer, effective March 1, 2016.  Full Article

bluebird bio and ViroMed Enter into License Agreement for Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
Thursday, 3 Dec 2015 08:00am EST 

bluebird bio, Inc. and ViroMed Co., Ltd:Says they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed's humanized antibody to an undisclosed cancer target for solid tumors.Under the terms of the agreement, ViroMed will provide bluebird bio exclusive rights to its novel humanized antibody to the target, and bluebird bio will leverage its lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.Financial terms of the agreement include a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved.ViroMed is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities.  Full Article

More From Around the Web

BRIEF-Bluebird bio Q1 total revenue $6.8 million

* Bluebird bio reports first quarter 2017 financial results and recent operational progress